Sickle Cell Disease: Targeting Alloantibody formation Reduction (STAR) - Risk factors for alloantibody formatio

Completed

• Conditions: Alloimmunisation in blood transfusion recipients; Formation of antibodies against foreign red blood cells after blood transfusion; 10018902

• Registration Number: NL-OMON41526
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

- Sickle Cell Disease (phenotypes HbSS, HbSC, HbS*+, HbS*0 or HbSE)
- History of at least 1 RBC transfusion in one of the participating centers

Exclusion Criteria

None

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameters are:<br /><br>- Immunogenetic determinants that could determine alloimmunisation; Variations<br /><br>in the gene cluster encoding the Fc-gamma receptors and the SIRP-alpha receptor<br /><br>(Signal Regulatory Protein-alpha).<br /><br>- Clinical determinants that could determine alloimmunisation such as gender,<br /><br>SCD genotype, geographic origin, age, age of first transfusion and number of<br /><br>transfusions.<br /><br><br /><br>The main study outcome is the cumulative incidence of allo-antibody formation<br /><br>in response to RBC transfusion. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>